Literature DB >> 10231073

Holistic versus composite preferences for lifetime treatment sequences for type 2 diabetes.

L D MacKeigan1, B J O'Brien, P I Oh.   

Abstract

This study of patient preferences for lifetime treatment sequences for type 2 diabetes had three objectives: to assess the feasibility of obtaining holistic preference assessments using the time-tradeoff (TTO) technique; to compare composite and holistic preference scores for the same lifetime treatment paths; and to assess the validity of composite and holistic preference measures in terms of their congruence with an individual's rank-order preferences. 101 persons with type 2 diabetes provided preference ratings for hyperglycemic treatments lasting 30 years, including eight discrete treatment states and four treatment paths. Scenarios described drug and glucose-testing regimens, efficacy of glucose control, and side effects. After ranking and rating scenarios on a thermometer scale, subjects provided TTO preferences for each treatment state or path scenario. Holistic assessment of treatment paths was feasible with the TTO technique, in terms of useable data (88% of interviews) and effect on coefficients of variation. Holistic and composite preference scores were not statistically different. Agreement was poor between rankings implied by holistic and composite scores and direct rankings. The authors conclude that lifetime treatment paths with minor differences in health effects can be assessed using either composite (QALY) or holistic (HYE) measures. The validity of these TTO-based preference measures remains unknown.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10231073     DOI: 10.1177/0272989X9901900201

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  5 in total

1.  Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease.

Authors:  Maureen P M H Rutten-van Mölken; Martine Hoogendoorn; Leida M Lamers
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 2.  Patient preferences for the treatment of type 2 diabetes: a scoping review.

Authors:  Susan M Joy; Emily Little; Nisa M Maruthur; Tanjala S Purnell; John F P Bridges
Journal:  Pharmacoeconomics       Date:  2013-10       Impact factor: 4.981

3.  Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma.

Authors:  Timothy A Howell; Louis S Matza; Monika P Jun; Jacob Garcia; Annette Powers; David G Maloney
Journal:  Pharmacoecon Open       Date:  2022-02-07

4.  Acute and chronic impact of cardiovascular events on health state utilities.

Authors:  Louis S Matza; Katie D Stewart; Shravanthi R Gandra; Philip R Delio; Brett E Fenster; Evan W Davies; Jessica B Jordan; Mickael Lothgren; David H Feeny
Journal:  BMC Health Serv Res       Date:  2015-04-22       Impact factor: 2.655

5.  Health state utilities associated with treatment for transfusion-dependent β-thalassemia.

Authors:  Louis S Matza; L Clark Paramore; Katie D Stewart; Hayley Karn; Minesh Jobanputra; Andrew C Dietz
Journal:  Eur J Health Econ       Date:  2019-12-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.